Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma by Davar, D et al.
Davar et al. Exp Hematol Oncol  (2015) 4:34 
DOI 10.1186/s40164-015-0029-7
CASE REPORT
Near complete response after single 
dose of nivolumab in patient with advanced 
heavily pre-treated KRAS mutant pulmonary 
adenocarcinoma
Diwakar Davar1, Mark A. Socinski1,3, Sanja Dacic2 and Timothy F. Burns1,4*
Abstract 
The programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 
normally expressed by infiltrating immune cells in response to viral infection. The PD-1/PD-L1 axis is a negative 
inhibitory pathway that down-regulates T-cells but is also used by tumors to evade anti-tumor immunity. Antibodies 
targeting PD-1/PD-L1 axis are capable of restoring functional anti-tumor immunity and have demonstrated efficacy in 
a broad range of tumor types including non-small cell lung cancer in both squamous and adenocarcinoma histolo-
gies. Ongoing issues affecting clinical development of these agents include assessment of response, optimal duration 
of therapy in excellent responders, predictive biomarkers and mechanisms of resistance. In this report, we describe 
a patient with advanced KRAS mutant heavily pretreated pulmonary adenocarcinoma who developed an excellent 
response after a single-dose of nivolumab. Pre-treatment tumor was found to have moderate CD3 and PD-L1 positiv-
ity by immunohistochemical staining. Evaluation of exceptional responders and non-responders are critical to further-
ing our understanding of the mechanisms of action (and resistance) to these agents.
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Background
In the past decade, large scale sequencing efforts 
unraveled the role of molecular driver events in the eti-
opathogenesis of non-small cell lung cancer (NSCLC), 
primarily in adenocarcinoma. Molecular targeted thera-
pies designed to exploit these weaknesses have trans-
formed the management of the minority of patients with 
advanced adenocarcinoma whose tumors harbor muta-
tions in epidermal growth factor receptor (EGFR) or rear-
rangements in anaplastic lymphoma kinase (ALK) or 
c-ros oncogene 1 (ROS1). Unfortunately, little progress 
has been made in the treatment of patients with the most 
frequently observed driver oncogene, mutant KRAS. 
KRAS is mutated in one-third of all malignancies and 
approximately 25  % of all NSCLC [1]. Further, acquired 
resistance to the currently targetable driver mutations 
is all but inevitable [2, 3]. Moreover, the prognosis of 
patients whose tumors do not harbor these genetic 
changes or those who progress on these agents continue 
to be treated with chemotherapy and have a median sur-
vival of 10–12 months.
Programmed death 1 (PD-1) receptor is an inhibi-
tory T cell receptor expressed by activated T-cells and 
engaged by ligands PD-L1 and PD-L2 of the B7-ligand 
superfamily normally expressed by infiltrating immune 
cells in response to viral infection. PD-1/PD-L1 axis 
constitutes a negative regulatory mechanism by which 
T-cell activation is homeostatically regulated; but is 
hijacked by tumors to circumvent effective anti-tumor 
immunity [4–6]. PD-1 blockade has been explored as an 
immunotherapeutic strategy with resounding success in 
immunogenic tumors (melanoma, renal cell carcinoma, 
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urothelial carcinoma) and additionally in tumors not 
formerly thought immunogenic including squamous 
NSCLC. Regulatory approval in squamous NSCLC was 
granted in early 2015 on the basis of improved survival 
compared to docetaxel in a 2nd line phase III study 
though activity has been reported in non-squamous 
NSCLC as well [7]. In these (and other studies) patients 
are typically first evaluated for response at 12  weeks. 
Herein, we report a patient with advanced KRAS mutant 
pulmonary adenocarcinoma treated with nivolumab after 
progressing on multiple therapies who had a remarkable 
response after just a single dose.
Case presentation
A 77-year-old African-American female heavy current 
smoker presented with dyspnea in September 2012. Ini-
tial computer tomography imaging revealed bilateral 
upper lobe masses with mediastinal lymphadenopathy 
and bilateral pulmonary and pleural nodules consistent 
with malignancy. Biopsy revealed CK7/TTF-1 positive 
adenocarcinoma. Molecular studies were notable for 
a KRAS exon 2 (pG12C, c.34G>T) mutation and TP53 
(pR283P, c.848G>C) but otherwise negative for 48 other 
key cancer genes as determined by the Ampliseq Cancer 
Hotspot Panel v2 including EGFR/BRAF/PIK3CA muta-
tions, ALK/ROS1/KIF5B/RET rearrangements and MET 
amplification.
She received 10 fractions of radiation therapy (RT) to 
mediastinum, then carboplatin and pemetrexed for 4 
cycles with a partial response that lasted 5 months before 
progressing in June 2013. Between June 2013 and Janu-
ary 2015, she received docetaxel, an investigational FAK 
inhibitor, gemcitabine and pemetrexed. In January 2015, 
she developed non-infectious pericarditis and spinal 
metastases requiring RT during which systemic therapy 
was interrupted till May 2015. Restaging scans docu-
mented further pulmonary and mediastinal lymph node 
progression with no evidence of extra-thoracic metas-
tases. She then received nivolumab 3  mg/kg on May 
20, 2015. Two weeks after her first dose, she was subse-
quently admitted for failure to thrive and dysphagia and 
was found to have a severe esophageal stricture near the 
GE junction secondary to extrinsic compression. She 
was subsequently discharged to a skilled nursing facil-
ity with plan for hospice. Two weeks after discharge, a 
dramatic clinical improvement was observed (weight 
gain, resolution of dysphagia and improved perfor-
mance status) and the patient was seen in clinic. Her 
course was subsequently complicated by exacerbation of 
chronic obstructive pulmonary disease (COPD) requir-
ing admission at which time a restaging CT scan was 
obtained, then convalescence in a nursing home, which 
precluded further nivolumab administration despite a 
remarkable improvement in dysphagia and performance 
status. Restaging scans showed marked regression in 
dominant parenchymal lung masses and para-esophagal 
lymph node commensurate with improving performance 
status and subjective dysphagia. She has since received 3 
further doses of nivolumab with ongoing response on last 
restaging scans on November 13, 2015.
Discussion
This report highlights the significant depth and duration 
of responses possible in select patients treated with PD-1 
inhibitor therapy (see Fig. 1). Similar dramatic responses 
have been observed with use of PD-1 inhibitors in other 
malignancies but this marks the first report of such a dra-
matic response in a patient with NSCLC with non-squa-
mous histology [8].
Programmed death 1 (PD-1) receptor is expressed 
by activated T-cells and engaged by ligands PD-L1 and 
PD-L2. PD-1/PD-L1 axis constitutes a negative regula-
tory mechanism by which T-cell activation is homeostati-
cally regulated; and is hijacked by tumors to circumvent 
effective anti-tumor immunity. Currently PD-1 inhibitors 
are approved for the treatment of BRAF V600 mutated 
and wild-type melanoma, advanced renal cell carcinoma 
and NSCLC with ongoing regulatory phase III trials in a 
host of other diseases including glioblastoma, head and 
neck carcinoma, small cell lung cancer, microsatellite 
unstable colorectal cancer, hepatocellular carcinoma, sar-
coma, and Hodgkin’s lymphoma [9, 10]. In NSCLC, PD-1 
blockade is only effective in 20–30 % of NSCLC patients 
with a 1-year survival rate of 42 % that declines to 18 % 
at 3 years [11]—much lower than in other malignancies 
such as melanoma and Hodgkin’s lymphoma. Predic-
tive biomarkers of PD-1 therapy are urgently needed in 
general but especially in NSCLC where patients often 
have significant co-morbidities necessitating upfront use 
of the most efficacious agents. Notably, in this patient, 
pre-treatment tumor tissue demonstrated PD-L1 and 
CD3 staining of moderate intensity suggesting a possible 
explanation for the outstanding response observed (see 
Fig. 2).
PD-1/PD-L1 staining is highly contextual and depends 
on the disease and treatment setting. Evaluation of PD-1/
PD-L1 staining in archival samples indicates that stain-
ing varies widely in solid tumors being highly expressed 
in certain tumors (melanoma, sarcoma) but minimally in 
others (hepatocellular carcinoma) [12]. Within tumors, 
PD-1/PD-L1 expression appears to be prognostic—being 
associated with poorer prognoses in multiple tumor 
types including testicular germ cell tumors and pros-
tate cancer [13, 14]. The observation of PD-L1 upregu-
lation on leukemic cells in patients on treatment with 
bi-specific antibodies likely represents development of 
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Fig. 1 Changes in Bi-dimensional tumor measurements of target and non-target lesions. Computer tomography (CT) scans depict imaging studies 
done on 5/13/2015 (above) and 7/15/2015 (middle). Lower graph depicts changes in size of target and non-target lesions at both time-points. 
Tumors were evaluated using Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Left axis depicts maximal bi-dimensional measurement for 
4 (1 target and 3 non-target) lesions while right axis depicts sum of maximal bi-dimensional measurements for all 4 lesions. All measurements are 
in mm. Nivolumab 3 mg/kg was administered on 5/20/2015 but subsequent doses were missed given multiple admissions. Prior to resumption of 
therapy following multiple admissions, a restaging scan was repeated on 7/15/2015. Remarkably, all lesions had shrunk considerably with 2 non-
target lesions (left pleural nodule and para esophageal lymph node) disappearing completely after a single dose of nivolumab. Patient received 3 
doses of nivolumab between 7/8/2015 and 8/12/2015. Therapy is ongoing with continued response
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a T-cell-induced immune escape mechanism—and sug-
gests that PD-1/PD-L1 inhibition may be complemen-
tary to these therapies in this setting [15, 16]. It is likely 
that the most accurate biomarkers will incorporate ele-
ments that reflect the dynamic and complex nature of the 
immune system including tumor mutation burden and 
T-cell infiltrate [17, 18]. Close interrogation of the host, 
tumor and tumor microenvironment in both extraordi-
nary responders and primary non-responders to PD-1 
therapy will be critical to this effort.
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